Analyst Activity – Cantor Fitzgerald Reiterates Overweight on Ardelyx (NASDAQ:ARDX)

15

Analyst Ratings For Ardelyx (NASDAQ:ARDX)

Today, Cantor Fitzgerald reiterated its Overweight rating on Ardelyx (NASDAQ:ARDX) with a price target of $12.00.

There are 4 buy ratings on the stock.

The current consensus rating on Ardelyx (NASDAQ:ARDX) is Buy (Score: 3.00) with a consensus target price of $16.50 per share, a potential 171.60% upside.

Some recent analyst ratings include

  • 5/19/2017-Cantor Fitzgerald Reiterated Rating of Overweight.
  • 5/15/2017-Citigroup Inc Reiterated Rating of Buy.
  • 2/15/2017-Wedbush Reiterated Rating of Outperform.
  • 3/31/2016-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.

Dividend information for Ardelyx (NASDAQ:ARDX)

.
Recent Insider Trading Activity For Ardelyx (NASDAQ:ARDX)
Ardelyx (NASDAQ:ARDX) has insider ownership of 15.46% and institutional ownership of 81.65%.

  • On 4/18/2017 David P. Rosenbaum, Insider, sold 2,051 with an average share price of $11.98 per share and the total transaction amounting to $24,570.98. View SEC Filing
  • On 3/3/2017 Jeremy S. Caldwell, EVP, sold 1,026 with an average share price of $14.14 per share and the total transaction amounting to $14,507.64. View SEC Filing
  • On 12/16/2016 David P Rosenbaum, SVP, sold 900 with an average share price of $14.48 per share and the total transaction amounting to $13,032.00. View SEC Filing
  • On 10/11/2016 Jeffrey W. Jacobs, SVP, sold 6,000 with an average share price of $15.00 per share and the total transaction amounting to $90,000.00. View SEC Filing
  • On 9/23/2016 Elizabeth A Grammer, SVP, sold 5,000 with an average share price of $12.00 per share and the total transaction amounting to $60,000.00. View SEC Filing
  • On 9/19/2016 Elizabeth A. Grammer, SVP, sold 6,859 with an average share price of $11.21 per share and the total transaction amounting to $76,889.39. View SEC Filing
  • On 7/18/2016 Nea 15 Gp, Llc, Major Shareholder, bought 1,527,301 with an average share price of $8.73 per share and the total transaction amounting to $13,333,337.73. View SEC Filing

About Ardelyx (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company’s cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Recent Trading Activity for Ardelyx (NASDAQ:ARDX)
Shares of Ardelyx closed the previous trading session at 6.07 down -0.33 -5.08% with 544,252 shares trading hands.

An ad to help with our costs